Menu

Jefferies Thinks ADMA Biologics’ Stock Is Going To Recover

Jefferies analyst Anthony Petrone maintained a Buy rating on ADMA Biologics on March 22 and set a price target of $10.00. The company’s shares closed last Thursday at $1.83, close to its 52-week low of $1.57.

According to TipRanks.com, Petrone is a 4-star analyst with an average return of 11.8% and a 60.4% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Haemonetics, and Cooper Co.

ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $7.67, which is a 328.5% upside from current levels. In a report issued on March 25, Raymond James also maintained a Buy rating on the stock with a $6.00 price target.

Based on ADMA Biologics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.96 million and GAAP net loss of $19.41 million. In comparison, last year the company earned revenue of $12.04 million and had a GAAP net loss of $10.56 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.